16:38 , Jul 18, 2019 |  BC Innovations  |  Distillery Therapeutics

Gossamer's CR3 agonist sensitizes pancreatic cancer to therapies

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Gossamer Bio Inc.'s CR3 agonist, GB1275, could sensitize pancreatic cancer to chemotherapy, radiation and immunotherapy. A team co-led by Rush University's Vineet Gupta, who co-founded Gossamer-acquired Adhaere Pharmaceuticals Inc.,...
19:15 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Checkmate raises $22M as Krieg hands off CEO role

Checkmate Pharmaceuticals Inc. (Cambridge, Mass.) said on Dec. 12 it completed a $22 million extension of its series B round and hired Barry Labinger to succeed co-founder Arthur Krieg as president and CEO. New investor...
00:50 , Dec 13, 2018 |  BC Extra  |  Financial News

Checkmate raises $22M as Krieg hands off CEO role

Checkmate Pharmaceuticals Inc. (Cambridge, Mass.) said Wednesday it completed a $22 million extension of its series B round and hired Barry Labinger to succeed co-founder Arthur Krieg as president and CEO. New investor Decheng Capital...
23:59 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest a vaccine based on a tetanus toxoid-MUC1 conjugate could help treat MUC1-expressing breast cancer. The conjugate consists of a 22-mer human MUC1 peptide conjugated to tetanus toxoid carrier protein,...
22:00 , May 18, 2018 |  BC Extra  |  Company News

Management tracks: Seattle Genetics, SurModics

Antibody-drug conjugate company Seattle Genetics Inc. (NASDAQ:SGEN) said CMO Jonathan Drachman has stepped down. He is succeeded by Roger Dansey, who was therapeutic area head for late-stage oncology at Merck & Co. Inc. (NYSE:MRK). Medical...
00:27 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Biothera begins Phase Ib/II trial of Imprime PGG plus Keytruda in NSCLC

Biothera Pharmaceuticals Inc. (Eagan, Minn.) began an open-label, U.S. Phase Ib/II trial to evaluate IV Imprime PGG plus IV Keytruda pembrolizumab in up to 36 patients with non-small cell lung cancer (NSCLC) whose cancer worsened...
02:22 , Feb 24, 2017 |  BC Week In Review  |  Clinical News

Imprime PGG: Ph II started

Biothera began an open-label, U.S. Phase II trial to evaluate IV Imprime PGG plus IV Keytruda pembrolizumab in up to 71 patients with advanced melanoma who have progressed on treatment with a checkpoint inhibitor therapy...
20:26 , Dec 9, 2016 |  BC Week In Review  |  Company News

Biothera, Merck deal

Merck and Biothera expanded an August deal to include an open-label Phase II trial of Biothera’s Imprime PGG in combination with Merck's cancer drug Keytruda pembrolizumab as second- and third-line treatment in 87 patients with...
00:59 , Oct 15, 2015 |  BC Extra  |  Company News

Management tracks

Cell programming company Fate Therapeutics Inc. (NASDAQ:FATE) said Scott Wolchko will succeed Christian Weyer as president and CEO following Weyer's resignation on Nov. 30. Wolchko was Fate's CFO. Fate also named Daniel Shoemaker CSO and...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Imprime PGG: Phase II started

Biothera said the Dana-Farber Cancer Institute began an open-label, U.S. Phase II trial to evaluate 4 mg/kg IV Imprime PGG plus IV Rituxan rituximab once weekly for 4 weeks in about 25 patients. Biothera Inc....